General
Preferred name
LEVOFLOXACIN
Synonyms
Levofloxacin (-)-ofloxacin ()
Levofloxacin hydrate ()
Levaquin hydrate ()
Tavanic hydrate ()
Quixin hydrate ()
Iquix hydrate ()
Cravit hydrate ()
(-)-Ofloxacin ()
Fluoroquinolone ()
Levaquin ()
Cravit ()
Tavanic ()
Levofloxacin Hemihydrate ()
LEVOFLOXACIN ANHYDROUS ()
Levofloxacin (hydrate) ()
Levofloxacin (hydrochloride) ()
LEVOFLOXACINN/A ()
(-)-Ofloxacin (hydrochloride) ()
L-ofloxacin ()
Oftaquix ()
RWJ-25213 ()
Levofloxacin (as hemihydrate) ()
Iquix ()
Ofloxacin, (s)- ()
Levofloxacin hemihydrate ()
Ofloxacin s-(-)-form hemihydrate ()
Floxacin ()
Ofloxacin s-(-)-form ()
Nofaxin ()
Quixin ()
DR-3355 ()
Evoxil ()
Volequin ()
NSC-758709 ()
Quinsair ()
LEVOFLOXACIN HYDROCHLORIDE ()
Levofloxacin-d8 (hydrochloride) ()
P&D ID
PD001207
CAS
138199-71-0
100986-85-4
177325-13-2
2699607-50-4
Tags
natural product
drug
available
Approved by
FDA
First approval
1996
Drug Status
investigational
approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Levofloxacin is a broad-spectrum, third-generation fluoroquinolone antibacterial. (GtoPdb)
Cell lines
5
Organisms
10
Compound Sets
24
AdooQ Bioactive Compound Library
A10528
A16167
Cayman Chemical Bioactives
20382
29080
ChEMBL Approved Drugs
CHEMBL33
ChEMBL Drugs
CHEMBL33
Drug Repurposing Hub
DrugBank
DB01137
DrugBank Approved Drugs
DB01137
DrugCentral
1569
DrugCentral Approved Drugs
1569
DrugMAP
DMS60RB
DrugMAP Approved Drugs
DMS60RB
Enamine BioReference Compounds
Guide to Pharmacology
10911
MedChem Express Bioactive Compound Library
HY-B0330
HY-B0330A
HY-B0330B
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
RIX4E89Y14
NIH Clinical Collections (NCC)
NPC Screening Collection
Pandemic Response Box
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
levofloxacin-levaquin
TargetMol Bioactive Compound Library
T6567
T1451
The Pathogen Box
External IDs
79
Properties
(calculated by RDKit )
Molecular Weight
361.14
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
2
cLogP
1.54
TPSA
75.01
Fraction CSP3
0.44
Chiral centers
1.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Disease
REFERENCE COMPOUNDS
Pathway
DNA Damage/DNA Repair
Anti-infection
Cell Cycle/DNA Damage
Target
DNA gyrase
Topo II
Topo IV
TOP2A
antibiotic
Bacterial
DNA/RNA Synthesis
Orthopoxvirus
Topoisomerase
MOA
DNA gyrase inhibitor
Topoisomerase inhibitor
bacterial DNA gyrase inhibitor
Indication
pneumonia, sinusitis, bronchitis, skin infections, prostatitis, urinary tract infections, pyelonephritis, anthrax, plague
respiratory tract infections, sinusitis, skin infections, bone and joint infections, intra-abdominal infections, diarrhea, fever, urinary tract infections
Disease Area
infectious disease, otolaryngology, gastroenterology, endocrinology
infectious disease, otolaryngology, pulmonary, urology
Therapeutic Indication
Antibacterial
Therapeutic Class
Antimicrobial
Antibiotics
Source data